Sciwind Biosciences Initiates the Patient Dosing of Ecnoglutide (XW003) in P-III Clinical Trials for the Treatment of Type 2 Diabetes in China
Shots:
- The first P-III study evaluates ecnoglutide (qw, SC) in ~210 treatment-naïve patients at ~35 sites in China & the second P-III trial evaluates XW003 vs dulaglutide in ~600 patients at ~60 sites in China for 52wks. followed by a 5wk. follow-up period
- In the P-I & II studies, Ecnoglutide showed treatment benefits for patients with T2D and obesity & was found to be safe and well tolerated. The therapy also showed robust HbA1c & weight reductions in the P-II trial
- Ecnoglutide is a novel, long-acting glucagon-like peptide-1 analog that has been designed for improved biological activity, cost-effective manufacturing, and qw dosing. The company plans to initiate the pivotal study of ecnoglutide for obesity shortly
Ref: PR Newsswire | Image: Sciwind
Related News:- Sciwind Biosciences Reports P-IIb Trial Interim Results of XW003 (ecnoglutide) for the Treatment of Obesity
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
